Navigation Links
Therapy in Biological Technology

The Breast Cancer Therapeutics Market in Australia

... This, combined with aggressive and targeted therapy has, in turn, resulted in a reduction in the ... targeted therapies as effective forms of cancer therapy is becoming more prevalent. These therapies are ... attributed to the fact that the use of targeted therapy is limited due to access and affordability ...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

... Structures by Delivery of PDGF Gene therapy Vectors, (Jin, et al., Mol Ther , 2004 April; ... for Clinical Use, (Chang, et al., Human Gene therapy , 2009 May; 20: 486-496). This body of research ... the potential safety and benefits of PDGF gene therapy for periodontal tissue repair and regeneration. ...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

... ever to test a combination gene and stem cell therapy for cardiovascular disease." The U.S. ... an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue ... for acute heart damage, and MyoCell((R)) SDF-1, a therapy utilizing autologous cells that are genetically ...

Patton Medical Devices Partners With Unomedical to Develop and Market the i-port Advance(TM) Injection Port for People Taking Multiple Daily Injections

... which, like us, believes in the injection port therapy market opportunity. With the i-port ... Medical Devices towards promoting injection port therapy combined with our expertise in designing and ... provider of infusion sets for insulin pump therapy worldwide since the mid 1980's, and currently ...

NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region

... for Pylera (R) , an innovative 3-in-1 capsule therapy for the eradication of Helicobacter pylori , a ... used in a wide range of patients as a first-line therapy for the eradication of Helicobacter pylori ... with Axcan for the Pylera 3-in-1 capsule therapy for Helicobacter pylori eradication, NewBridge ...

REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients

... of all ages who are started on antidepressant therapy should be monitored appropriately and observed ... or within 14 days of initiating or discontinuing therapy with an MAOI. In US controlled clinical ... associated with REMERON(R) (mirtazapine) Tablets therapy were: somnolence (54%), increased appetite (17%), ...

OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance

... cost. Our service helps those patients stay on therapy by seeking funds to offset their cost." In ... for safe and supervised use of these oral therapy treatments. The pharmacy utilizes oncology ... monitor patient compliance with the prescribed therapy and support adherence by helping patients manage ...

Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia

... family to look after them. Autologous cell therapy has been studied as an innovative treatment ... cells therefore making widespread adoption of the therapy problematic. The Harvest trial utilized the BMAC ... the Indian Society of Vascular Surgery where the therapy will be considered for designation as a standard ...

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

... previous Phase 2 results with this combination therapy and provide a solid foundation for the Company's ... obesity drug development." The combination therapy was well tolerated, and no cardiovascular or ... in a balanced fashion to receive twice-daily therapy with one of the following eight treatment ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Definitions and Scope of Study I-3 Hormonal therapy I-3 Radiation therapy I-4 Chemotherapy I-4 Surgical Procedures ... of FDA Approved Prostate Cancer Hormonal therapy Drugs in the US for 2007 (includes corresponding ...

Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial

... to identify patients who could benefit from this therapy and monitor its effect. Together, this diagnostic ... outcomes and mortality compared with conventional therapy alone, in a targeted patient population with ... and 53% (16/30 patients) in the conventional therapy group. - Mean Arterial Pressure (MAP) ...

Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections

... the product as an adjunct to systemic antibiotic therapy for treating moderately infected ulcers compared to systemic therapy alone. For patients randomized to the treatment ... to 80% in the control group receiving standard therapy alone. Comprehensive results from this trial are ...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

... separate rounds of treatments received third-line therapy (also called second salvage) with ... refractory / relapsed AML today have no standard therapy as existing therapies are inadequate for most ... it has the potential to become the standard of therapy for refractory / relapsed AML. An elacytarabine ...

FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout

... controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. The current target ... one product: KRYSTEXXA(TM) (pegloticase) as a therapy for patients with treatment failure gout, to ...

Three Rivers Announces Positive Results from Phase 3 DIRECT Trial of Once-Daily INFERGEN(R) with Ribavirin in Hepatitis C Virus Treatment Failures

... Interferon and Ribavirin: Efficacy of Combined therapy (DIRECT) clinical trial authored by Bruce R. ... failing to respond to standard, first-line therapy of pegylated interferon (PEG-IFN) plus ribavirin ... strategy for patients failing previous therapy with PEG-IFN/RBV, especially in ...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

... biopharmaceutical company focused on endocrine therapy and oncology, today reported that patient ... announced that patients completing two years of therapy with cetrorelix in the first efficacy study ... biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug ...

New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance

... effectiveness of newest class of antiretroviral therapy MADISON, N.J., June 12 ... so they may more quickly determine or change therapy based on how the HIV virus infects cells in the ... identify suitable patients for a particular therapy and ensure those who are not suitable do not lose ...

Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)

... Currently, there is no FDA approved intravenous therapy for reduction of fever other than Caldolor. ... of oral ibuprofen formulations, an alternative therapy for pain and fever in the hospital setting where ... adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in ...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

... biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an ... Zentaris, patients completing two years of therapy in the North American trial of cetrorelix, ... biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug ...

New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives

... - The surveyed patients were either on biologic therapy or were biologic naive but eligible for biologic ... arthritis live with their disease and how therapy may impact their ability to manage their RA," ... the perceptions of their patients and their unmet therapy needs. The survey was conducted October through ...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

... biopharmaceutical company focused on endocrine therapy and oncology, today disclosed preliminary results ... a 35% local control rate, one year after end of therapy in the placebo group. It was hypothesized that ... biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug ...

Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter

... pulmonary thromboembolism when anticoagulant therapy is contraindicated, failure of anticoagulant therapy in thromboembolic diseases, emergency treatment ... PE, and chronic recurrent PE when anticoagulant therapy has failed or is contraindicated. The nitinol, ...

Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions

... patient-friendly approach to deliver exenatide therapy for the treatment of type 2 diabetes," said K. ... and tolerability of ITCA 650." ITCA 650 therapy in this phase 1b trial was administered for the ... injections. About ITCA 650 ITCA 650 therapy for type 2 diabetes consists of DUROS continuous ...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

... - Company Also Granted Expansion of Prophylaxis therapy Label to Include Patient Labeling for ... was approved as the first and only targeted therapy for routine prophylaxis against angioedema ... we look forward to a day when this important therapy will be approved in the acute setting." ...

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

... Vancocin is currently the only FDA approved therapy for CDI. Recurrence Rates by Subgroup (per ... cure defined as patients requiring no further CDI therapy two days after completion of study medication, as ... evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea ...

Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

... chemotherapy, the standard of care for first line therapy in this disease. Fifty-three percent of pixantrone patients received four or more cycles of therapy compared to a median of three cycles in the ... median doxorubicin equivalent dose at the end of therapy was 513 mg/m2 (with a range of 115 mg/m2 to ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... historical response rates for docetaxel as solo therapy in advanced breast cancer patients and it ... I clinical trial evaluating bavituximab as solo therapy in patients with advanced refractory cancer will ... not be improved as a result of the combination therapy with the inclusion of bavituximab . It is ...

Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients

... have had an inadequate response to conventional therapy and for the treatment of adults with moderately ... with active infection. Empiric anti-fungal therapy should be considered in patients at risk for ... be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... of nimotuzumab in combination with radiation therapy (RT) or chemoradiation therapy (CRT) in patients with inoperable (Stage III or ... Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy ...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

... biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented ... prostatic LHRH receptors to deliver cytotoxic therapy based on LHRH analogs, such as AEZS-108. ... biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug ...

Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting

... or who are receiving concurrent cyclophosphamide therapy Acute infusion-related ... may occur after discontinuation of anthracycline therapy For patients with a history of ... indicate possible cardiac injury, the benefit of therapy must be weighed against the risk of myocardial ...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

... investigators better understand the mechanism of therapy resistance so they may develop more effective, ... include: -- Resistance to imatinib therapy (Gleevec(R)) in patients with chronic myeloid ... "confer significant drug resistance" to imatinib therapy by expressing a truncated BCR-ABL1. Abstract ...

Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients

... transplant recipients. Prograf is a cornerstone therapy for preventing transplant rejection in liver, ... and reinforces the importance of this combination therapy in the treatment of kidney and heart transplant ... Only physicians experienced in immunosuppressive therapy and management of organ transplant patients ...

Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions

... dose arms at the ADA Conference." ITCA 650 therapy in this phase 1 trial is administered for the full course of therapy with a single insertion of the DUROS device on ... injections. About ITCA 650 ITCA 650 therapy for type 2 diabetes consists of DUROS continuous ...

Physician's Organization Makes History by Publishing U.S.'s First Adult Stem Cell Guidelines (ASCTA Drives Safe Stem Cell Practices)

... The American Stem Cell therapy Association (ASCTA) announced today the ... CO (PRWEB) May 19, 2009 -- The American Stem Cell therapy Association ( ASCTA ) announced today the ... with standards under which adult stem cell therapy can be practiced safely. These stem ...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

... biopharmaceutical company focused on endocrine therapy and oncology, today announced that results ... cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor. Lead ... biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug ...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

... IL-21 Plus Sorafenib as Second- or Third-Line therapy for Metastatic Renal Cell Cancer ... lung cancer, ovarian cancer, and as an adjuvant therapy for kidney cancer and liver cancer. ... hypertension may occur early in the course of therapy and blood pressure should be monitored weekly ...

Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions

... defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) patients. Schedule of ... will sponsor the "Tenth Annual Essentials of CRM therapy and Patient Management," chaired by Mark Heimann, ... grouped by the percent biventricular pacing therapy they receive. The results will be presented ...

Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout

... or condition for which there is no adequate therapy available. In January, the Company ... consequences in patients for whom conventional therapy is contraindicated or has been ineffective. The ... and efficacy of a six-month course of pegloticase therapy in patients with treatment failure gout, under ...

AMT Starts Preregistration Trial for Glybera(TM)

... trial with Glybera(TM). This gene therapy product targets lipoprotein lipase deficiency ... of all patients is more than 45 years. The therapy was well tolerated and no drug-related severe ... Therapeutics AMT has a unique gene therapy platform that to date appears to circumvent many ...
Other Contents
(Date:7/10/2014)...  Aware, Inc. (NASDAQ: AWRE ), a ... on June 26, 2014 that its Board of Directors ... share, or approximately $40 million in total.  The Board ... a payment date of July 24, 2014.  The Company ... an ex-dividend date for this special cash dividend.  An ...
(Date:7/10/2014)... , July 2, 2014  Unisys Corporation,s (NYSE: ... Unisys Nederland N.V., today announced that it has been selected ... and manage a new Basic Provision Biometrics solution for penitentiaries ... Unisys won the contract with a solution based on its ... The term of the contract is up to seven years, ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4
(Date:7/11/2014)... (PRWEB) July 11, 2014 Butler Mobility has ... Inclined Platform Lifts . Previously the two standard ... five new beautiful earth tone colors as standard colors at ... well in the home but will enhance the beauty of ... for any home color scheme or individual décor. , The ...
(Date:7/11/2014)... July 11, 2014 Microbiology testing is ... in-vitro diagnostics industry, which is expected to pose the ... The sector owes its growth to the ongoing spread ... health worldwide and a major factor leading to the ... of bio-terrorism, and a broader availability of immunosuppressants, among ...
(Date:7/11/2014)... Rochester, NY (PRWEB) July 11, 2014 ... Surgery ’s own, Dr. William Koenig, has topped a ... his peers, he has performed over 400 successful procedures ... , Dr. Koenig is well known across the country ... His exceptional safety record has long been the foundation ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... comes to the summer concert schedule, it just isn’t complete without ... of the biggest names in country music and one of the ... his “That’s My Kind of Night” tour featuring Lee Brice and ... through the rest of the summer and into the fall includes ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
Other TagsOther Tags